Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management

Cited by (508)

Items 301–400 of 508

1. Cost-utility of pre-emptive plerixafor versus rescue plerixafor in the mobilization of hematopoietic stem cells in multiple myeloma
   Tallys Kalynka Feldens, Roselene Mesquita Augusto Passos, Juliana de Oliveira Martins · 2026 · Expert Review of Pharmacoeconomics & Outcomes Research
2. Rho-related GTP-binding protein RhoE (RND3) regulates multiple myeloma bone disease
   Qianwen Gao, Wenjiao Tang, Ziyue Mi, Siyao He, Haonan Yang, Fangfang Wang, Jingcao Huang, Yue Zhang, Jingjing Wen, Linfeng Li et al. · 2026 · Cancer Cell International
3. Spectrum of blood viscosity, albumin/fibrinogen ratio, and red cell distribution width in newly diagnosed multiple myeloma patients: an observational study
   Muhamad R. Abdel Hameed, Ahmed Radwan Abdel-hakim Rostom, Maiada Kamal · 2025 · The Egyptian Journal of Haematology
4. Recent Updates and Advancements in the Diagnosis and Management of Plasma Cell Dyscrasias
   Anand Sunil, Ahnaf Uddin Ahmed, Ahmed Elkhider Ali Musa, Arzoo Dar, Nafrin Kormath, Sai Lahari Sangaraju, Nejma Azeez, Bashir Imam, Vinay Dontul, Sweta Singh et al. · 2026 · Cureus
5. Comparative Efficacy of Daratumumab Based Regimens in Patients With Relapsed‐Refractory Multiple Myeloma ( RRMM ) Aged 70 and Above: A Multicenter Study
   Razan A. Mansour, Kimberly M. Green, Chandler Graf, Mark Chang, Gray Magee, James A. Davis, Anas Zayad, Nausheen Ahmed, Muhammad Umair Mushtaq, Evguenia Ouchveridze et al. · 2026 · European Journal Of Haematology
6. Normal SFLC Ratio in Newly Diagnosed Myeloma: A Potential Biomarker of Non‐High‐Risk and Nonaggressive Disease
   Man Singh, Yadav Sanjeev, Akshita Pandey, Khaliqur Rahman, Mona Vijayaran, Poorvi Kapoor, Sayan Sinha Roy, Ruchi Gupta, Dinesh Chandra, Kaushal Kumar et al. · 2026 · International Journal of Laboratory Hematology
7. Independent prognostic factors predicting survival in multiple myeloma patients post-chemotherapy: a retrospective study
   Yuan Luo, Tao Jiang, Li Liu · 2026 · Hematology
8. Saudi experts statement on advancing multiple myeloma treatment: the evolving role of bispecific antibodies
   Ghazi Alotaibi, Ahmad S. Alsaeed, Majed D. Alahmadi, Abdullah Alamer, Abdullah S. Al Saleh, Ahmed Salleh Barefah, Saud Alhayli, Enas Yahya Mutahar, Omar Abduljalil, Hesham Kiwan et al. · 2026 · Frontiers in Medicine
9. CD56 negativity is associated with worse survival outcomes in patients with multiple myeloma: a meta-analysis
   Guiyang Zhu, Shenchao Zhu, Fei Yang, Qin Tang · 2026 · World Journal of Surgical Oncology
10. Predicting High-Risk Multiple Myeloma Based on Multiparametric MRI Radiomics and Deep Learning
    清源 张 · 2026 · Advances in Clinical Medicine
11. Mielomul multiplu: progrese recente în diagnostic și tratament (Review integrativ)
    Gheorghe BURUIANA, Leonid Chislaru, Victor Schiopu, Sanda Buruiana · 2026 · Akademos
12. Romiplostim N01 accelerates platelet engraftment in autologous stem cell transplantation using non-cryopreserved peripheral blood stem cells for plasma cell neoplasms
    Xianfu Sheng, Qijia Zheng, Jingjing Xiang et al. · 2026 · Research Square
13. Lenalidomide maintenance after delayed or salvage autologous stem cell transplantation
    Asad A. Haider, Curtis Marcoux, Denái R. Milton et al. · 2026 · Leukemia & lymphoma/Leukemia and lymphoma
14. Atorvastatin Protects Against Deleterious Carfilzomib-Induced Transcriptional Changes in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
    Marwa Tantawy, DanXin Wang, Mohammed O. Gbadamosi · 2026 · International Journal of Molecular Sciences
15. Bystander or perpetrator: Unravelling the significance and challenges of MGUS
    Malini Surapaneni, Jacob S. Edmisson, Attaya Suvannasankha, Kelvin P. Lee, Ola Landgren, Rafat Abonour · 2026 · Blood Reviews
16. Longitudinal profiling of serum ADAM17 across clinical stages in multiple myeloma: a dynamic biomarker and its association with T cell alterations
    Jiao Qu, Yancheng Li, Chenchen Li · 2026 · Frontiers in Molecular Biosciences
17. Cutting‐Edge Technologies to Decode Tumor Microenvironment in Multiple Myeloma
    Doriana Gramegna, Paolo Mondelli, Susanna Anita Pappagallo, Grazia Gargano, Maria Carmela Vegliante, Angela Maria Quinto, Bernardo Rossini, Gianvito Pasciolla, Aldo Maria Roccaro, Michele Cea et al. · 2026 · Hematological Oncology
18. PET imaging of XPO1 engagement with [18F]selinexor: A pharmacodynamic theranostic strategy for multiple myeloma
    Xinlin Zhong, Lizhen Wang, Junjie Yan, Chen Su, Xinyu Wang, Donghui Pan, Yuping Xu, Chongyang Chen, Min Yang · 2026 · Bioorganic Chemistry
19. Genomic Proximity Mapping for Identification of Chromosomal Aberrations in Multiple Myeloma
    Richard K. Kandasamy, Joel-Sean Hsu, Steve Eacker et al. · 2026 · American Journal of Hematology
20. Melphalan in the biologic era: A 70-year story in hematological malignancies and its legacy, evolution, and future
    Biswajit Bhuyan, Simoni Bhooshan Pandit, Rupak Kumar Giri · 2026 · Journal of Hematology and Allied Sciences
21. CD138-targeted bispecific protein engager-armed T cells exhibit potent and selective cytotoxicity against multiple myeloma cells
    Pucharee Songprakhon, Piriya Luangwattananun, Kornkan Choomee, Nunghathai Sawasdee, Chalermchai Somboonpatarakun, Thaweesak Chieochansin, Sanya Sukpanichnant, Mutita Junking, Seiji Okada, Pa‐thai Yenchitsomanus · 2026 · International Immunopharmacology
22. The Art of Deception: Multiple Myeloma Imitating Spondyloarthritis—A Case Report
    Prabin Khatri, Aabishkar Subedi, Bimal Dahal · 2026 · Clinical Case Reports
23. Netupitant/palonosetron is effective for preventing chemotherapy-induced nausea and vomiting in high-dose melphalan conditioning before autologous stem cell transplantation: A real-world analysis
    Leqing Cao, J. Dai, Ting Wang et al. · 2026 · Blood Science
24. Anti-myeloma activity of the CXCR4 antagonist WZ811
    Dana Cholujová, Nikoleta Csicsatkova, Zuzana Valuskova · 2026 · Journal of Molecular Medicine
25. Comparison of the prognostic value of the neutrophil to lymphocyte ratio with other prognostic indices in the prognosis of patients diagnosed with multiple myeloma
    Ngoc Dung Nguyen, Minh Phuong Vu, Hoang Vu · 2026 · World Academy of Sciences Journal
26. Surveillance of Smoldering Myeloma Patients Who Progress to Active Disease Is Associated with Favorable Outcomes
    Gil Fridberg, Inbar Cohen, Renana Robinson, Iuliana Vaxman, Tamir Shragai, Svetlana Trestman, Tomer Ziv‐Baran, Natan Melamed, Pia Raanani, Irit Mazza Avivi et al. · 2026 · Cancers
27. Daratumumab in the Treatment of Multiple Myeloma: Real World Evidence (2018-2024) at the a. Gemelli Polyclinic (Rome) and Comparison With Registration Studies
    Michele Favia, Marco Sperandeo, Lidia Di Cerbo · 2026 · Hospital Pharmacy
28. An evaluation of elranatamab for the treatment of myeloma: current evidence for treating relapsed/refractory disease and future directions
    Elena Bayly-McCredie, Henry Miles Prince, Costas Kleanthes Yannakou, Salvatore Fiorenza, Brendan Wisniowski · 2026 · Expert Opinion on Biological Therapy
29. Hämatologische Neoplasien und solide Tumore
    Arnold Ganser, Bernd Hertenstein, Wolf‐Dieter Ludwig · 2026 · Springer eBooks
30. Discovery of 2-(methylamino)-5,6,7,8-tetrahydropyrido[4,3-d] pyrimidine derivatives as novel HsClpP activators for multiple myeloma therapy
    Xiang Liu, Jinglong Gu, Yan Liu · 2026 · European Journal of Medicinal Chemistry
31. Integrative approaches to plasma cell disorders
    Krisstina L. Gowin · 2026 · Elsevier eBooks
32. [68Ga]Ga-Pentixafor PET/CT for Durie-Salmon PLUS staging and risk stratification in newly diagnosed multiple myeloma
    Jie Chen, Shuaihu Tang, Li Liu · 2026 · European Journal of Nuclear Medicine and Molecular Imaging
33. A Multi-Omics and machine learning platelet-related prognostic signature in multiple myeloma
    Xiaojing Li, Qirong Xiao, Kuangfei Wang, Xiaobin Lin, Yuan He, Jun Peng, Nainong Li, Hai Zhou, Ping Chen · 2026 · Annals of Hematology
34. Investigating the functions and molecular mechanisms of DTX3L in cancer progression
    Haiyu Mu, Mengwen Han, Hejuan Hu, Xilin Xu, Haojian Wang, Feng Zhu, Yongxia Wu, Liangqian Jiang, Y Chen · 2026 · Frontiers in Oncology
35. Quadruplet daratumumab in combination with bortezomib, lenalidomide, and dexamethasone as front-line regimen improved clinical outcomes in high-risk myeloma patients in China: a multi-centered prospective real-world study
    Lili Cheng, Dong Liang, J L Jia, Runfeng Zhang, Yang Yang, Peng Liu, Hongli Sun, Xiaoqi Qin, Yanping Ma, Yue Wu et al. · 2026 · BMC Cancer
36. Real-World Treatment Patterns of Elranatamab in Patients with Multiple Myeloma in Japan: The EVEREST Study
    Satoshi Yoshihara, Aster Meche, Patrick Hlavacek et al. · 2026 · ClinicoEconomics and Outcomes Research
37. Temporal bone plasmacytoma: An exceptional localization of solitary bone plasmacytoma highlighting the role of multimodal imaging and multidisciplinary management
    Mohammed Amine Rabhi, Saad Bouchlarhem, Achraf Amine Sbai · 2026 · Radiology Case Reports
38. PPRC1 is a prognostic biomarker and key regulator of mitochondrial oxidative phosphorylation in multiple myeloma
    Y. Liu, Siqi Yan, Xuemei Shu · 2026 · Annals of Medicine
39. Maintenance Strategies in High-Risk Myeloma: A Multicenter Comparison of Bortezomib–Lenalidomide Versus Lenalidomide Alone: A USMIRC Multicenter Analysis
    Sruthi Priyavadhana Ramanan, Oyepeju Folashade Abioye, Shebli Atrash, Jianzheng Wu, Dinesh Pal Mudaranthakam, Anita Mazloom, Omar Abed Alkharabsheh, Mansi R. Shah, Zahra Mahmoudjafari, Jordan Andrew Snyder et al. · 2026 · Current Oncology
40. METTL16 enhances proteasome inhibitor resistance in multiple myeloma by inhibiting eIF2α-PERK interaction and promoting PSMB5 translation.
    Guanli Wang, Xue-Jie Gao, Hui Zhang, Ke Hu, Qilin Feng, Yujie Liu, Chao-Lu Hu, Shu-Shan Guo, Dan-Dan Yu, Shuai-Kang Chang et al. · 2026 · Oncogene
41. Descriptive Study of Current Routine Clinical Practice in the Management of Patients With Multiple Myeloma in Spain: CROMMAS Study
    Enrique M. Ocio, M. Teresa Álvarez Mateos · 2026 · Clinical Lymphoma Myeloma & Leukemia
42. Absence of CD38 expression in mantle cell lymphoma correlates with distinct pathological and genetic features
    Sara Abu Mehsen, Fnu Monika, Shidhant Sharma · 2026 · Human Pathology
43. Burden of disease for multiple myeloma in China and the Asia–Pacific region, 1990–2021: a systematic analysis of the Global Burden of Disease (GBD) 2021 study
    Sen-Xin Wang, Tao Luo, Ni Yang, Xun-Ru Liu, Yan-Ping Ma · 2026 · Annals of Hematology
44. Choosing Wisely in First Relapse of Multiple Myeloma: Expert Insights on Treatment Selection
    Samer Al Hadidi, Caitlin L. Costello, Luciano J. Costa, Binod Dhakal, Peter Georges, Ajeet Gajra, Yi Lin, Ranjana S. Bhargava, Agne Paner-Straseviciute, Ravi Vij · 2026 · Clinical Lymphoma Myeloma & Leukemia
45. Global, Regional, and National Burdens and Trends of Multiple Myeloma in Men Aged 60 Years and Older: An Analysis using the Global Burden of Disease Database (1990-2021)
    Hui Sun, Lixiang Yan, Lijun Fang · 2026 · Research Square
46. Molecular Pathology of Mature Lymphoid Neoplasms
    Gabriel C. Caponetti, Adam Bagg · 2026 · Surgical pathology clinics
47. Gammapathie monoclonale de signification indéterminée : approche diagnostique et diagnostics différentiels
    Bénédicte Piron, Cyrille Touzeau · 2026 · EMC - Traité de médecine AKOS
48. Final clinical data of a phase 1 dose‐escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with γ‐secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myeloma
    Fredrik Hellem Schjesvold, Andrew G Spencer, Yael Chava Cohen, Enrique M. Ocio, Jordi López‐Pardo, Anna Maria Cafro, Natalie S. Callander, Jonathan L. Kaufman, Meera Mohan, Martin Wermke et al. · 2026 · Cancer
49. The Evolving Role of Genomic Technologies in Multiple Myeloma: Implications for Diagnosis, Risk Stratification and Resistance
    Klára Baďurová, Veronika Kapustová, Jana Kotulová, Vítězslav Brinsa, Lenka Piherová, Václav Janoušek, Michal Pohludka, Michal Richtář, Tomáš Jelínek, Roman Hájek et al. · 2026 · Molecular Diagnosis & Therapy
50. Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients
    Hira Imad Cheema, Asis Shrestha, Syed Naqvi, Sanjay Muttineni, Sasya Dronavalli, Jawad A. Alrawabdeh, Marah Alzubi, Carolina Schinke, Sharmilan Thanendrarajan, John D. Shaughnessy et al. · 2026 · Blood Cancer Journal
51. Single-cell technologies in deciphering drug resistance of multiple myeloma: mechanistic insights and clinical translation prospects
    Jun Wu, Haibo Dong, Xuejing Xu, Mei Wang · 2026 · Leukemia & lymphoma/Leukemia and lymphoma
52. A randomized comparison of etoposide and cyclophosphamide for stem cell mobilization in newly diagnosed multiple myeloma
    Yao Sun, Jieping Li, Yujun Dong et al. · 2026 · Scientific Reports
53. Treatment Discontinuation After Achieving MRD Negativity in Multiple Myeloma in the Pre‐BCMA Era: A Prospective, Single‐Centre Study
    Kota Sato, Kenshi Suzuki, Shotaro Sugita, Ukyo Kondo, Miyu Watanabe, Moe Nomura‐Yogo, Tomomi Takei, Mizuki Ogura, Yu Abe, Taku Kikuchi et al. · 2026 · eJHaem
54. Case Report: Bone marrow metastasis revealing gastric signet ring cell carcinoma: a case report
    Sarra Ben Azouz, Myriam Ayari, Sarra Ben Rejeb · 2026 · F1000Research
55. Cardiac Light Chain (AL) Amyloidosis
    Eugène Brailovski, Heather Jolie Landau · 2026 · Elsevier eBooks
56. BAR and LAR as mortality predictors in critically ill multiple myeloma patients: a MIMIC-IV study
    Haitao Xu, Caihong Jiang, Dangui Chen, Jia Lu, Lihong Wang, Fei Chen, Long Zhong · 2026 · Research Square
57. The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non–Secretory Relapse—A Retrospective Cohort Study
    Iuliana Vaxman, Itai Zamir, Inbar Cohen et al. · 2026 · Hematological Oncology
58. Risk for second primary malignancies in patients with multiple myeloma: a systematic review and meta-analysis
    Yingjie Tian, Liang Su, Yujin Li, Minlan Ye, Yuchu Zhang, Q Q Li, Yongzheng Jiao, Jie Wu · 2026 · Frontiers in Oncology
59. Amiloidosis conjuntival AL como manifestación inicial de mieloma múltiple
    S. Melgar Martín, M.I. Soler Sanchis, L. Pérez Zaballos · 2026 · Archivos de la Sociedad Española de Oftalmología
60. Vaccination of immunosuppressed patients
    Marton Skog Steinberger König, Trygve Holmøy, Gro Owren Nygaard et al. · 2026 · Tidsskrift for Den norske legeforening
61. Patterns of care in relapsed/refractory multiple myeloma in China: a real-world physician survey study
    D. Wu, Bhavna Murali, Otávio Clark · 2026 · Future Oncology
62. Proteomic profiling revealed unique disease biology associated with 1q abnormalities in multiple myeloma
    Kiran Kumar Mangalaparthi, Joel-Sean Hsu, Julia Erin Wiedmeier et al. · 2026 · npj Precision Oncology
63. Conjunctival AL amyloidosis as the initial manifestation of multiple myeloma
    S. Melgar Martín, M.I. Soler Sanchis, L. Pérez Zaballos · 2026 · Archivos de la Sociedad Española de Oftalmología (English Edition)
64. Comparison of adverse event profiles of carfilzomib-, elotuzumab-, and ixazomib-based therapies combined with lenalidomide and dexamethasone in patients with multiple myeloma using VigiBase
    Jun Matsumoto, Tatsuaki Takeda, Shiho Sugimoto, Tomonori Sakai, Beatrix Bermudo Loyao, Tsukasa Higashionna, Hirofumi Hamano, Gerard Lee See, Noritaka Ariyoshi, Yoshito Zamami · 2026 · Leukemia Research
65. Clinical characteristics, laboratory measures, and quality of life as predictors of medication adherence in multiple myeloma
    Nizar Abu Hamdeh, Mohammad Alnees, Ibraheem AbuAlrub et al. · 2026 · Scientific Reports
66. Romiplostim N01 accelerates platelet engraftment in autologousstem cell transplantation using non-cryopreserved peripheral blood stem cells for plasma cell neoplasms
    Xianfu Sheng, Qijia Zheng, Jingjing Xiang et al. · 2026 · Frontiers in Immunology
67. Mass spectrometry-based proteomics and metabolomics in multiple myeloma: a systematic review of prognostic biomarkers and minimal residual disease monitoring
    Naseel Moursy, Hibba Siraj, Zainab Nasir · 2026 · Frontiers in Medicine
68. Plasma expression of long non-coding RNA GAS5 and its prognostic significance in newly diagnosed multiple myeloma
    Anica Divac, Nataša Tos̆ić, Zorica Cvetković · 2026 · Frontiers in Oncology
69. Acute liver failure as an initial presentation of multiple myeloma
    Naddya Olivero Danies, Martín Milanesio, Ana Victoria Sanchez · 2026 · JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
70. Research and Advances in Sphingolipid Metabolism in Hematological Malignancies
    芷柔 张 · 2026 · Advances in Clinical Medicine
71. Defining High-Risk Disease Biology in Multiple Myeloma: A Narrative Review
    Mohammad Aljumaa, Hasan Hamam Refai, Yogesh Kumar Chawla, Wilson I. Gonsalves · 2026 · Blood and Lymphatic Cancer Targets and Therapy
72. The mechanisms of regulatory T cells in the immune microenvironment of multiple myeloma and clinical significance
    Lijun Du, Yumeng Jiang, Qiaolin Zhou, Fang Xu · 2026 · Frontiers in Immunology
73. Serum ICTP as a Marker of Bone Resorption and Its Association with Hematological and Biochemical Parameters in Multiple Myeloma
    Shahad Mahir Habeeb, Hind Shaker Abuob · 2026 · European Journal of Medical and Health Research
74. RAD23A promotes multiple myeloma cell survival through DNA damage response, proteostasis and enhanced metabolic activity
    Hongxiu Liu, Yihua Wang, Xunru Liu, Ni Yang, Senxin Wang, Jie Zhao, Yaqi Shi, H W Wang, Yanping Ma · 2026 · Toxicology and Applied Pharmacology
75. Signal Detection and Machine Learning-Based Prediction of Cytokine Release Syndrome in B-Cell Maturation Antigen-Targeting Immunotherapies Using FAERS Data
    Suhyeon Moon, Dong-Won Kang, Yeo Jin Choi, Sooyoung Shin · 2026 · Pharmaceuticals
76. Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working group
    Wenming Chen, Zhen Cai, Chor Sang Chim, Wee Joo Chng, Juan Du, Chengcheng Fu, Wen Gao, Ichiro Hanamura, Jian Hou, Jeffrey Shang-Yi Huang et al. · 2026 · Clinical Hematology International
77. Delving into tRNA-derived small RNAs in multiple myeloma: elevated 3′U-tRFSerTGA leads to poor disease prognosis
    Konstantinos Soureas, Panagiotis Malandrakis, Maria‐Alexandra Papadimitriou et al. · 2026 · British Journal of Cancer
78. Liver as the First Witness: Two Rare Cases of Systemic AL Amyloidosis Presenting with Hepatomegaly
    Neelkumar Patel, Anamika Bakliwal, Swati Saxena et al. · 2026 · Indian Journal of Hematology and Blood Transfusion
79. CCT2 regulates the proliferation, apoptosis, and cell cycle arrest of multiple myeloma cells through the P53 signalling pathway
    Hongxiu Wang, Xiaomin Chen, Yang Liu, S K Wang, Qiuyu Xiang, Yu Zhao, Lixiu Luo, Yue Wu, Chunlan Huang · 2026 · Scientific Reports
80. Copy Number Alterations Suggest a Functional Switch from Innate Immunity to DNA Repair and Drive Clinical Heterogeneity in Plasma Cell Dyscrasias
    Igor Valentim Barreto, Wallax Augusto Silva Ferreira, Guilherme Passos de Morais, Jéssica Sousa Cavalcante, Caio Bezerra Machado, Flávia Melo Cunha de Pinho Pessoa, Leidivan Sousa da Cunha, Anna Karolyna da Costa Machado, Isabelle Magalhães Farias, Beatriz Maria Dias Nogueira et al. · 2026 · International Journal of Translational Medicine
81. Multiple myeloma mortality in Latin America: Heterogeneous patterns and challenges in cross-country comparisons
    Bryan Valcarcel-Valdivia, Eloísa Riva, Camila Peña · 2026 · Cancer Epidemiology
82. BCMA‐Engineered Dendritic Cell‐Derived Exosomes as Bi‐Functional Therapeutics Orchestrating Cytokine Sequestration and Immune Activation for Multiple Myeloma
    Yuqing Zeng, Chao He, Zhibin He, Hongbo Chen, Fang Cheng, Y Zheng · 2026 · Advanced Science
83. Staged Surgical Resection of Giant Multicentric Cranial Plasma Cell Neoplasms: A Case Report
    Hugo Eduardo Mora Moreno, Fernando Villicaña Díaz, Cesar Alí Duran Ramírez, Luis F Silva Pantoja, Ingrid Olvera Franco · 2026 · Cureus
84. Frailty score analysis of multiple myeloma patients in the evaluation prior to autologous hematopoietic stem cell transplantation
    Felipe de Menezes Cunha, Hércules Amorim Mota Segundo, Lívia Andrade Gurgel et al. · 2026 · JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
85. Sociodemographic, Clinical, and Therapeutic Characterization of Multiple Myeloma Patients (CharisMMa Study) with Symptomatic Relapse and/or Refractory Disease: An Observational, Multicenter Study in Portugal
    Rui Bergantim, José Guilherme Freitas, Cristina Gonçalves, Helena Martins, Herlander Marques, Henrique Guimaraes Barbosa Coelho, Patrícia Seabra, Adriana Isabel Roque, Márcio Tavares, Pedro Pinto et al. · 2026 · Hematology Reports
86. Molecular insight into the interplay among heterogeneous plasmacytes and microenvironment cells and their clinical relevance in myeloma
    Lu Jiang, Cheng-Lin Liu, Yu-Liang Zhang, Niu Qiao, Jianfeng Li, Shuangshuang Yang, X Shen, Meng-Ping Chen, Sheng-Yue Wang, Ting Wu et al. · 2026 · Proceedings of the National Academy of Sciences
87. Plasma Cell Neoplasms
    Andrés E. Quesada, Pei Lin · 2026 · Cambridge University Press eBooks
88. Application of the New IMWG/IMS High-Risk Classification for Multiple Myeloma: Analysis of a Large Real-World Romanian Cohort
    Sorina Nicoleta BADELITA, Sinziana Barbu, Onda-Tabita Călugăru · 2026 · International Journal of Molecular Sciences
89. Feasibility of post-induction consolidation with BCMA CAR-T cell therapy in newly diagnosed multiple myeloma not proceeding to ASCT: A preliminary case series
    Jiaying Wu, Rubing Zheng, Xi Ming · 2026 · Cell Transplantation
90. Clinical Characteristics, Treatment Patterns, and Prognosis of Central Nervous System Involvement in Multiple Myeloma: A Multicenter Retrospective Study From China
    Wenjing Li, Weiwei Tian, Jie Ma et al. · 2026 · Cancer Medicine
91. Clinical implications of minimal residual disease monitoring in multiple myeloma
    Takeshi Yoroidaka · 2026 · International Journal of Hematology
92. Toxicity Under-Reporting in Early-Phase Plasma Cell Dyscrasia Clinical Trial Abstracts
    Dawn Swan, Marsali Maclean, Niamh Waters · 2026 · JCO Oncology Practice
93. Identification and validation of prognostic genes related to centrosome amplification in multiple myeloma
    Pengjun Liao, Jiaqi Tan, Lingji Zeng · 2026 · PeerJ
94. CD70-targeted platform for diagnosing and treating multiple myeloma
    Jun Li, Haoyi Yan, X G Wang et al. · 2026 · Journal for ImmunoTherapy of Cancer
95. Patterns of care for older multiple myeloma patients in the U.S.: An analysis of the national cancer database
    Muni Rubens, Jeremy I Purow, Daniel M Portnoy, Alejandra Viera Plasencia, Julia Steger, Sofia Steger, Feng Go Ho Wu, Jorge Valdés, Vicente Abreu Fernández, Vicente Antonio Gea Caballero et al. · 2026 · Current Problems in Cancer
96. Outpatient step-up dosing of bispecific antibodies in relapsed or refractory multiple myeloma: an oncology nursing framework for monitoring and supportive care
    Yanfeng Song, Xiaofei Zhou, Lina Wang · 2026 · Frontiers in Oncology
97. Stage-specific disruption of erythropoiesis leads to anemia in newly diagnosed multiple myeloma patients
    Shihui Wang, Wenna Fu, C F Chen et al. · 2026 · Frontiers in Cell and Developmental Biology
98. Clinical mismatches leading to the misdiagnosis of multiple myeloma as diabetic nephropathy: A case report
    LI Gui-zhi, Jia-Yin Liu, Hui-Yao Hao · 2026 · World Journal of Diabetes
99. Early Soluble B-Cell Maturation Antigen (BCMA/TNFRSF17) Kinetics as a Molecular Biomarker of Treatment Response in Multiple Myeloma Patients
    Laura Caponi, Maria Livia Del Giudice, Silvia Ursino, Alice Botti, Alberto Gennari, Aldo Paolicchi, Riccardo Morganti, Gabriele Buda · 2026 · International Journal of Molecular Sciences
100. Biclonal gammopathy with coexistent proximal tubulopathy and cast nephropathy in multiple myeloma: a rare case report
     Shanshen Yu, Jia Sun, Xufeng Mei · 2026 · BMC Nephrology